RU2006143659A - Применение ребоксетина для лечения боли - Google Patents

Применение ребоксетина для лечения боли Download PDF

Info

Publication number
RU2006143659A
RU2006143659A RU2006143659/152006143659/15A RU2006143659A RU2006143659A RU 2006143659 A RU2006143659 A RU 2006143659A RU 2006143659 A RU2006143659 A RU 2006143659A RU 2006143659 A RU2006143659 A RU 2006143659A
Authority
RU
Russia
Prior art keywords
pain
reboxetine
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
RU2006143659/152006143659/15A
Other languages
English (en)
Russian (ru)
Inventor
БернадетХЬЮЗ Бернадетт ХЬЮЗ (GB)т (GB)
Бернадетт ХЬЮЗ
Ян МАККЕНЗИ (GBМАККЕНЗИ Ян (GB))
Ян МАККЕНЗИ
МалколСТОКЕР Малкольм Джон СТОКЕР (GB)ьм Джон (GB)
Малкольм Джон СТОКЕР
Original Assignee
Пфайзер Инк. (Uпфайзер Инк. (Us)S)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Пфайзер Инк. (Uпфайзер Инк. (Us)S), Пфайзер Инк. filed Critical Пфайзер Инк. (Uпфайзер Инк. (Us)S)
Publication of RU2006143659A publication Critical patent/RU2006143659A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2006143659/152006143659/15A 2004-06-09 2005-05-27 Применение ребоксетина для лечения боли RU2006143659A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0412878.1 2004-06-09
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
US60/588,652 2004-07-16
GB0425061.9 2004-11-12
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
US60/634,427 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
RU2006143659A true RU2006143659A (ru) 2008-06-20

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006143659/152006143659/15A RU2006143659A (ru) 2004-06-09 2005-05-27 Применение ребоксетина для лечения боли

Country Status (12)

Country Link
US (1) US20080261984A1 (enExample)
EP (1) EP1763354A2 (enExample)
JP (1) JP2008501778A (enExample)
KR (1) KR20070029740A (enExample)
AU (1) AU2005256944A1 (enExample)
BR (1) BRPI0511941A (enExample)
CA (1) CA2567365A1 (enExample)
IL (1) IL178827A0 (enExample)
MX (1) MXPA06014389A (enExample)
NO (1) NO20064642L (enExample)
RU (1) RU2006143659A (enExample)
WO (1) WO2006000903A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20130310385A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
EP3782627A4 (en) * 2018-04-17 2021-07-07 Shanghai Tonglian Pharmaceutical Co., Ltd. MEDICINAL PRODUCT USED TO PREVENT AND / OR TREAT PAIN AND / OR FEVER, A COMBINATION PRODUCT, AND USE OF THEM
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
BR112021007019A2 (pt) * 2018-10-15 2021-07-13 Axsome Therapeutics, Inc. uso de reboxetina para tratar narcolepsia
US12616702B2 (en) * 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CR20220247A (es) * 2019-12-03 2022-08-18 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso
US20260174699A1 (en) * 2024-12-23 2026-06-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising uniform blends of reboxetine
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
MXPA06002778A (es) * 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern

Also Published As

Publication number Publication date
US20080261984A1 (en) 2008-10-23
MXPA06014389A (es) 2007-02-19
AU2005256944A1 (en) 2006-01-05
WO2006000903A2 (en) 2006-01-05
CA2567365A1 (en) 2006-01-05
WO2006000903A3 (en) 2006-06-08
IL178827A0 (en) 2007-03-08
NO20064642L (no) 2006-11-13
EP1763354A2 (en) 2007-03-21
JP2008501778A (ja) 2008-01-24
KR20070029740A (ko) 2007-03-14
BRPI0511941A (pt) 2008-01-22

Similar Documents

Publication Publication Date Title
ES2532849T3 (es) Tratamiento con agonista de la melatonina
JP2004520290A5 (enExample)
JPH08505133A (ja) 解熱方法および鎮痛方法並びに光学的に純粋なr−ケトロラックを含む組成物
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
EA200400881A1 (ru) Азаарилпиперазины
RU2009101324A (ru) Композиции и способы лечения воспаления слизистой оболочки
JP2006501240A5 (enExample)
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2020534270A5 (enExample)
EP2043637A4 (en) METHOD AND MEDICAMENTS FOR THE ADMINISTRATION OF IBUPROFEN
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
JP2013541583A5 (enExample)
RU2008141076A (ru) Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
BRPI0511941A (pt) uso de (s, s)-reboxetina ou reboxetina racêmica
RU2008127882A (ru) Лечение пищевода барретта
JP2008501778A5 (enExample)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
RU2006141647A (ru) Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
DE602007014193D1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
JP2021506907A5 (enExample)
RU2002124141A (ru) Применение миртазапина для лечения расстройств сна

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20081223

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20081223